Applied DNA Sciences, Inc.
APDN · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $13 | $18 | $9 |
| % Growth | -74.3% | -26.4% | 101.3% | – |
| Cost of Goods Sold | $2 | $8 | $13 | $4 |
| Gross Profit | $1 | $6 | $5 | $5 |
| % Margin | 29.6% | 41.4% | 27.8% | 54.6% |
| R&D Expenses | $4 | $4 | $4 | $4 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11 | $13 | $15 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Expenses | $15 | $16 | $19 | $17 |
| Operating Income | -$14 | -$11 | -$14 | -$12 |
| % Margin | -408.7% | -81.9% | -76.9% | -136.2% |
| Other Income/Exp. Net | $7 | $1 | $6 | -$2 |
| Pre-Tax Income | -$7 | -$10 | -$8 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$10 | -$8 | -$16 |
| % Margin | -203.8% | -74.4% | -46.1% | -177.6% |
| EPS | -1.82 | -15.21 | -18.68 | -46.35 |
| % Growth | 88% | 18.6% | 59.7% | – |
| EPS Diluted | -1.82 | -15.21 | -18.68 | -46.35 |
| Weighted Avg Shares Out | 4 | 1 | 0 | 0 |
| Weighted Avg Shares Out Dil | 4 | 1 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$13 | -$10 | -$13 | -$12 |
| % Margin | -388.4% | -71.7% | -69.8% | -129.4% |